Skip to main content

Bio-Rad Laboratories, Inc. (BIO) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $254.44 (-9.17%)

Consensus Target
$327.50
Upside
+22.8%
Analysts
2
Rating
Hold(3.00)

Price Target Range

Low $320.00Consensus $327.50High $335.00
▲ Current $254.44

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Hold
Strong Buy0
Buy0
Hold2
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Feb 16, 2026Brandon CouillardWells Fargo$320.00+25.8%
Oct 1, 2024Patrick DonnellyCitigroup$400.00+57.2%

BIO vs Sector & Market

MetricBIOHealthcare AvgLarge Cap Avg
Analyst Rating3.002.242.41
Analyst Count2818
Target Upside+22.8%+1150.2%+14.9%
P/E Ratio41.926.8331.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$2.59B$2.63B$2.67B3
2027-03-31$612M$613M$614M1
2027-06-30$683M$684M$685M1
2027-09-30$701M$702M$703M1
2027-12-31$739M$740M$741M1
2028-03-31$626M$627M$628M1
2028-06-30$699M$700M$701M1
2028-09-30$721M$721M$723M1
2028-12-31$759M$760M$761M1
2029-12-31$2.90B$2.94B$2.98B1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$10.10$10.29$10.472
2027-03-31$2.84$2.84$2.851
2027-06-30$2.79$2.79$2.801
2027-09-30$2.88$2.88$2.891
2027-12-31$3.29$3.29$3.301
2028-03-31$3.49$3.50$3.501
2028-06-30$3.16$3.16$3.171
2028-09-30$3.26$3.27$3.271
2028-12-31$3.43$3.44$3.441
2029-12-31$14.03$14.30$14.551

Frequently Asked Questions

What is the analyst consensus for BIO?

The consensus among 2 analysts covering Bio-Rad Laboratories, Inc. (BIO) is Hold with an average price target of $327.50.

What is the highest price target for BIO?

The highest price target for BIO is $400.00, set by Patrick Donnelly at Citigroup on 2024-10-01.

What is the lowest price target for BIO?

The lowest price target for BIO is $320.00, set by Brandon Couillard at Wells Fargo on 2026-02-16.

How many analysts cover BIO?

2 analysts have issued ratings for Bio-Rad Laboratories, Inc. in the past 12 months.

Is BIO a buy or sell right now?

Based on 2 analyst ratings, BIO has a consensus rating of Hold (3.00/5) with a +22.8% upside to the consensus target of $327.50.

What are the earnings estimates for BIO?

Analysts estimate BIO will report EPS of $10.29 for the period ending 2026-12-31, with revenue estimated at $2.63B.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.